1-3 of 3
Jing Lu, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BRD4 Proteolysis Targeting Chimera (PROTAC) Leads to Sustained Degradation of BRD4 with Broad Activity Against Acute Leukemias and Overcomes Stroma Mediated Resistance By Modulating Surface Expression of CXCR4

Sujan Piya, Teresa McQueen, Duncan Mak, BSc, MPhil, Marina Konopleva, MD PhD, Patrick Zweidler-McKay, MD PhD, Jing Lu, PhD, Yimin Qian, PhD, Michael Andreeff, MD PhD, Gautam Borthakur, MD
Journal: Blood
Blood (2015) 126 (23): 675.
https://doi.org/10.1182/blood.V126.23.675.675
Published: 2015
Journal Articles

Proteolytic Targeting Chimeric Molecules (PROTACs) Specific for Bromodomain-Containing Protein (BRD) 4 Are Active Against Pre-Clinical Models of Multiple Myeloma

Xiaohui Zhang, MD, PhD, Jing Lu, PhD, Yimin Qian, PhD, Robert Z. Orlowski, PhD, MD
Journal: Blood
Blood (2015) 126 (23): 917.
https://doi.org/10.1182/blood.V126.23.917.917
Published: 2015
Journal Articles

BRD4 Degradation By Protacs Represents a More Effective Therapeutic Strategy Than BRD4 Inhibitors in DLBCL

Jing Lu, PhD, Yimin Qian, PhD, Kanak Raina, PhD, Martha Altieri, MS, Hanqing Dong, PhD, Jing Wang, PhD, Xin Chen, PhD, Andrew Crew, PhD, Kevin Coleman, PhD, Craig Crews, PhD, James Winkler, PhD
Journal: Blood
Blood (2015) 126 (23): 2050.
https://doi.org/10.1182/blood.V126.23.2050.2050
Published: 2015